Blackstone Inc’s Bio-Rad Laboratories Class A BIO Stock Holding History

Blackstone Inc’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,162	Closed	-$603K	–	536
2026 Q1	$603K	Buy	+2,162	New	+$623K	﹤0.01%	282

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Blackstone Inc's BIO Position: Q2 2026 in Review

Blackstone Inc sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 2,162 shares — an estimated $603K sold.

Blackstone Inc first reported a position in BIO in Q1 2026 and held it in 1 quarter. The position peaked at $603K in Q1 2026. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Blackstone Inc reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
Blackstone Inc sold 2,162 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $603K.
Blackstone Inc first reported a position in Bio-Rad Laboratories Class A in Q1 2026 and held it in 1 quarter.
Blackstone Inc's Bio-Rad Laboratories Class A position peaked at $603K in Q1 2026.
398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.